Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DU385
- Development stage
- Preclinical
- Lead developer
- Avidin
- Modality
- Small Molecules
01
Overview
DU385 is a preclinical-stage small molecule imidazo[1,2-b]pyrazole-7-carboxamide derivative developed by Avidin. It is being investigated as an anti-cancer agent, particularly for the treatment of acute myeloid leukemia (AML) and colon cancer. DU385 induces differentiation-coupled apoptosis in human leukemia cells at nanomolar concentrations. Mechanistically, it induces oxidative stress, as evidenced by the depletion of cellular glutathione (GSH) and mitochondrial membrane depolarization, and alters the expression of endoplasmic reticulum (ER) stress-related and oxidative stress-related genes (such as ALOX5AP, TXN, and SOD1).
- Other names
- imidazo-pyrazole carboxamide derivativeimidazo[1,2-b]pyrazole-7-carboxamide derivative
Beyond the preview
Go deeper on DU385.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DU385.